ArticleLeukemia2021

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.

Massimo Gentile et al.PubMed ↗Publisher ↗

No numbers read from the abstract.